The stock of Enzo Biochem, Inc. (NYSE:ENZ) is a huge mover today! The stock increased 3.46% or $0.17 during the last trading session, hitting $5.09. About 312,548 shares traded hands or 129.67% up from the average. Enzo Biochem, Inc. (NYSE:ENZ) has risen 16.31% since February 26, 2016 and is uptrending. It has outperformed by 5.89% the S&P500.
The move comes after 7 months positive chart setup for the $229.88 million company. It was reported on Oct, 1 by Barchart.com. We have $10.13 PT which if reached, will make NYSE:ENZ worth $227.58M more.
Analysts await Enzo Biochem, Inc. (NYSE:ENZ) to report earnings on October, 11. They expect $-0.06 earnings per share, 0.00% or $0.00 from last year’s $-0.06 per share. After $-0.04 actual earnings per share reported by Enzo Biochem, Inc. for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.
According to Zacks Investment Research, “Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company’s three wholly-owned subsidiaries–Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company’s research is the development of products based on two technology platforms — genetic modulation and immune modulation.”
Insitutional Activity: The institutional sentiment decreased to 1.38 in 2016 Q2. Its down 0.12, from 1.5 in 2016Q1. The ratio fall, as 16 funds sold all Enzo Biochem, Inc. shares owned while 24 reduced positions. 25 funds bought stakes while 30 increased positions. They now own 24.06 million shares or 13.07% more from 21.28 million shares in 2016Q1.
Federated Invsts Pa last reported 0% of its portfolio in the stock. State Street owns 494,216 shares or 0% of their US portfolio. Barclays Plc has 0% invested in the company for 60,680 shares. Northern Trust reported 464,684 shares or 0% of all its holdings. Tfs Capital Ltd Limited Liability Company has 150,022 shares for 0.16% of their US portfolio. The New Jersey-based Blackrock Invest Management Lc has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). D E Shaw And Inc owns 160,061 shares or 0% of their US portfolio. Jacobs Levy Equity Mgmt holds 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 30,739 shares. Schwab Charles Management accumulated 0% or 105,081 shares. Art Ltd owns 17,061 shares or 0.01% of their US portfolio. Moreover, Geode Capital has 0% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 289,986 shares. Voya Investment Mgmt Limited Liability Company last reported 22,377 shares in the company. Moreover, Bridgeway Capital Management has 0.03% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 308,200 shares. Granahan Investment Management Ma holds 857,942 shares or 0.19% of its portfolio. Blackrock Advisors Ltd Liability Company holds 0% or 19,949 shares in its portfolio.
More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Finance.Yahoo.com which released: “Enzo Biochem Announces New York State Health Department Approval of New Easily …” on September 20, 2016, also Businesswire.com with their article: “Enzo Biochem’s Life Sciences Unit Reaches $35 Million Patent Infringement …” published on May 16, 2016, Prnewswire.com published: “Lone Star Value Issues Open Letter to Shareholders of Enzo Biochem, Inc.” on December 22, 2015. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Businesswire.com and their article: “Enzo Biochem Announces New York State Approval of New Women’s Test Based on …” published on June 07, 2016 as well as Businesswire.com‘s news article titled: “Enzo Biochem Reaches $10 Million Patent Infringement Settlement with …” with publication date: October 13, 2015.
ENZ Company Profile
Enzo Biochem, Inc. (Enzo), incorporated on August 13, 1976, is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Firm operates through three divisions: Enzo Life Sciences, Enzo Clinical Labs and Enzo Therapeutics. Enzo Life Sciences segment makes, develops and markets products and tools to clinical research, drug development and bioscience research clients around the world. Enzo Clinical Labs segment provides diagnostic services to the health care community. Enzo Therapeutics segment conducts research and development activities for therapeutic drug candidates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.